A core aspect of our ethos is to develop products that are at the cutting edge of clinical nutrition, offering specialist supplements for therapeutic use. Our ongoing R&D process ensures that we regularly review scientific developments in nutraceuticals and their health application, as well as innovations in the sourcing of raw materials and delivery forms.
The effectiveness and bioavailability of different forms of omega-3 is a popular and ongoing debate. Indeed, this is a major reason that fish oil alternatives such as krill oil have gained popularity. Where they fail to offer benefits, however, is for clinical use. The doses offered by standard fish oils and especially krill oil, simply fail to produce therapeutic levels in the body.
Ethyl-ester versus triglyceride
We have long maintained that ethyl-ester forms of EPA and high concentrations of 70+% are the most suitable for clinical use, over and above the natural triglyceride forms of fish oil delivering 30% concentration of active ingredients EPA/DHA together. Until recently, ethyl-ester forms were the only form of high concentration EPA omega-3 at commercially viable prices (for food supplements as opposed to pharmaceutical drugs).
Although the safety and efficacy of ethyl-EPA is well established, with numerous trials showing clinical effects at high doses, ethyl-EPA absorption can be lower than natural triglyceride forms because its chemical structure is different and it requires additional fat molecules to aid digestion (for example, consuming fat at the same time).
With technological advancements and increased demand for EPA, there is now an alternative that offers the superior bioavailability of natural triglyceride fat molecules with the high concentration active doses of ethyl-esters – known as ‘re-esterified triglycerides’ (rTG). After the oil is concentrated in its ethyl-ester form, it is converted back to a triglyceride structure by re-attaching the fatty acids to a glycerol backbone. This produces an oil with high omega-3 EPA concentrations (like ethyl-ester form), but simultaneously enhances its absorption and delivery like the natural triglyceride oils. Studies show that rTG forms of omega-3 are so bioavailable that they offer greater absorption without the need for dosing with or after food, increasing the omega-3 index faster and more effectively than any other form of omega-3.
At Igennus, we are committed to offering the most premium, science-based supplements for therapeutic use so we are choosing to upgrade our products, starting with our highest EPA concentrate, Pharmepa Step 1: Restore, which utilises 1000 mg 90% EPA per dose in the rTG form for unprecedented concentration, purity and bioavailability. This supplement is the highest concentration, most bioavailable omega-3 EPA product on the market, offering exciting implications for clinical use. In addition, the recent re-launch of our improved and joint-targeted product Omegaflex also boasts the greater benefits of rTG EPA.